Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Look At Payers' Early Game Plans For Driving Biosimilar Use

Executive Summary

Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.

You may also be interested in...



Zarxio Coverage On Par With Innovators Even Without Interchangeable Designation

Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.

Zarxio Coverage On Par With Innovators Even Without Interchangeable Designation

Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.

Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up

High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel